A coalition of hemophiliacs who contracted HIV/AIDS due to improper guidance from pharmaceutical companies and NHF around blood safety file a class action lawsuit.

NHF enters a co-op agreement with the CDC to provide education, resources, and programming.

In 1993, the FDA issued a new guideline and formally rescinded the 1977 policy that banned most women from participating in studies. To ensure that the policies for inclusion were firmly implemented by NIH, the Congress made what had previously been policy into law, through a section in the NIH Revitalization Act of 1993.

Dr. Glenn Pierce, a physician with hemophilia, runs for NHF president on a platform of reforming the organization to meet the community’s demands. Pierce appointed Val Bias, a MANN leader, as chairman of the board once elected.

The first recombinant factor VIII (8) product is approved by the Food and Drug Administration (FDA).

Ryan White, a hemophilia and AIDs advocate, passes away from complications due to HIV.

The Human Genome Project begins.

W. French Anderson and his colleagues at the NIH perform the first approved gene therapy procedure on a four-year-old girl born with severe combined immunodeficiency.

An article in the Journal of Biological Chemistry announces that the structure of the gene for human von Willebrand factor is succesfully cloned for the first time.

NHF launches the Women’s Outreach Network of NHF (WONN) and the Men’s Advocacy Network of NHF (MANN).